ALNY
Alnylam Pharmaceuticals Inc
224.40$
+0.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.9% | -6.8% | -16.5% | 18.8% | 8.7% | -16.0% | -19.9% | 19.9% | 26.0% | 14.9% | 6.0% | 5.8% | 13.2% | |
| 3.1% | 3.1% | 2.7% | 2.3% | 9.7% | -3.5% | 2.4% | 1.8% | 1.1% | 1.2% | 1.2% | 1.1% | 1.1% | |
| 8.5% | 9.6% | 9.2% | 13.5% | 9.1% | 15.5% | 9.5% | 14.4% | 8.7% | 6.5% | 6.0% | 6.7% | 7.0% | |
| 21.7% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 3.4% | 1.5% | -24.5% | -7.5% | 6.1% | -12.5% | -36.5% | 6.5% | -16.4% | -6.7% | -24.1% | 2.3% | -11.0% | |
| 2.3% | 3.5% | 2.6% | 1.2% | 0.8% | 1.5% | 1.5% | 1.8% | 1.0% | 2.1% | 1.9% | 2.7% | 1.9% | |
| -1.4% | -54.7% | -13.7% | 5.1% | -6.0% | -8.9% | 19.1% | -18.3% | 40.1% | -3.4% | -2.2% | -28.2% | 1.6% | |
| – | – | – | – | – | – | – | – | – | -4.8% | – | – | – | |
| 4.4% | 8.9% | 5.8% | 19.9% | 20.5% | 5.2% | 7.4% | 6.9% | -35.9% | 4.1% | 1.3% | 1.8% | -7.6% | |
| 50.0% | -50.1% | -26.5% | 43.4% | 26.2% | -22.6% | 9.0% | 12.1% | 30.2% | 15.1% | 4.6% | -20.7% | 6.8% | |
| 45.6% | -10.3% | -19.1% | 17.6% | 7.9% | -17.5% | -21.4% | 18.0% | 25.1% | 12.8% | 4.2% | 3.1% | 11.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.